Join to celebrate the power of biotech at the Dutch Biotech Event 2023!
About HollandBIO’s Dutch Biotech Event
The program features inspiring talks by keynote speakers on biotech and entrepreneurship, followed by workshops and break-out sessions that contribute to your personal development and that of your company. In addition, there will be plenty of opportunities for networking during the break, drinks and vegetarian BBQ.
Practical information
Date: Friday, June 30th
Time: 12:45 pm – 20:00 pm, including drinks and vegetarian BBQ
Venue: InnStyle, Herenweg 55 Maarssen
Program
12:45-13:30 pm – Registration, coffee & tea
13:30-15:30 pm – Plenary program (line-up to be announced)
15:30-16:00 pm – Networking break
16:00-17:00 pm – Break-out sessions (topics to be announced)
17:00-20:00 pm – Networking drinks & vegetarian BBQ
Who can join Dutch Biotech Event?
The Dutch Biotech Event welcomes HollandBIO members (registration free of charge) and employees of other biotech R&D companies (registration fee €295,- p.p.), with a maximum of 2 delegates per organization.
We invite non-member startups to consider a HollandBIO membership (€562,-/year), which besides access to the network & events, offers many more advantages.
If you have any questions, please contact HollandBIO’s Dina to find out more about the options to join the event.
Registration
You can save your spot for the Dutch Biotech Event via this link. Use the ‘Tickets’ button on the right hand side to register.
Keynote speakers
Hans Schikan
Passionate Life Science Connector / Top Team Top Sector Life Science & Health
Hans brings some three decades of leadership experience in the (bio)pharmaceutical sector. After his graduation as a pharmacist, he was hired by Organon and traveled the world in various commercial roles. He then joined Genzyme where he became inspired by their efforts for rare disease patients. In 2008 Prosensa, a young company focusing on an mRNA therapy for Duchenne Muscular Dystrophy, approached him to become its CEO. During his leadership, Prosensa entered into a collaboration with GlaxoSmithKline, was listed on NASDAQ with a successful IPO in 2013 and was acquired by BioMarin early 2015 for up to USD 840 million. He currently serves on the board of several biotech companies (public and private) in the Netherlands, Belgium, the United Kingdom, Sweden and Switzerland, partly as chairman of the board. He is a member of the core team of the Dutch Top Sector for Life Sciences and Health, involved with Swanbridge Capital and Forty51 Ventures and co-founder/board member of Pharvaris, listed on NASDAQ. Finally, he was Special Envoy for vaccines, appointed by the Dutch Ministry of Health and Welfare, during part of the COVID-19 pandemic.
Joshua Cohen & Justin Klee
Co-CEOs & Co-Founders Amylyx
Josh Cohen and Justin Klee co-founded Amylyx in 2013 with the aim of understanding the causes of neuronal death in neurodegenerative diseases . By combining their expertise in biomedical engineering and neuroscience and in collaboration with the neurodegenerative disease community, they have grown Amylyx from a dorm room concept to a globally operating, publicly traded pharmaceutical company over the past 10 years. Amylyx’ investigational ALS treatment has received regulatory approval in Canada and the U.S., and the company is looking to serve the patient community globally, with European headquarters based in Amsterdam. Amylyx has a strong connection with the Netherlands’ ALS community and the Dutch biotech sector. Josh and Justin are driven each day by the company’s mission to end the suffering caused by neurodegenerative diseases like ALS by striving to discover and develop better therapies. In their presentation, Josh and Justin will talk about their journey with Amylyx and how they continually question the unquestioned to address significant unmet medical needs.